All Data
Development, Manufacturing & Marketing of Pharmaceuticals for Central Nervous System Pathologies.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Undisclosed
Partner/Sponsor/Collaborator: Permira Funds
Deal Size: $1,880.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 22, 2020
Details:
The Permira funds will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of Neuraxpharm’s attractive new product pipeline and support further its expansion internationally.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
